Nuclear Receptor ROR Gamma - Pipeline Review, H2 2016 - Key Vendors are AbbVie, Biogen & GlaxoSmithKline - Research and Markets
October 26 2016 - 11:19AM
Business Wire
Research and Markets has announced the addition of the "Nuclear
Receptor ROR Gamma - Pipeline Review, H2 2016" report to their
offering.
This report provides comprehensive information on the
therapeutic development for Nuclear Receptor ROR Gamma, complete
with comparative analysis at various stages, therapeutics
assessment by drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type, along with latest updates,
and featured news and press releases. It also reviews key players
involved in the therapeutic development for Nuclear Receptor ROR
Gamma and special features on late-stage and discontinued
projects.
The report enhances decision making capabilities and help to
create effective counter strategies to gain competitive advantage.
It strengthens R&D pipelines by identifying new targets and
MOAs to produce first-in-class and best-in-class products.
Companies Mentioned:
- AbbVie Inc
- Advinus Therapeutics Ltd
- Arrien Pharmaceuticals, LLC
- Aurigene Discovery Technologies Limited
- Beijing Hanmi Pharmaceutical Co., Ltd.
- Biogen Inc
- Brickell Biotech, Inc.
- Bristol-Myers Squibb Company
- Celgene Corporation
- Eli Lilly and Company
- Genentech, Inc.
- Genfit SA
- GlaxoSmithKline Plc
- Japan Tobacco Inc.
- Lead Pharma Holding B.V.
- Nuevolution AB
- Pfizer Inc.
- Phenex Pharmaceuticals AG
- Reata Pharmaceuticals, Inc.
- Takeda Pharmaceutical Company Limited
- Teijin Pharma Limited
- Visionary Pharmaceuticals, Inc.
- Vitae Pharmaceuticals, Inc.
Key Topics Covered:
- Introduction
- Nuclear Receptor ROR Gamma Overview
- Therapeutics Development
- Pipeline Products for Nuclear Receptor ROR Gamma -
Overview
- Pipeline Products for Nuclear Receptor ROR Gamma - Comparative
Analysis
- Nuclear Receptor ROR Gamma - Therapeutics under Development by
Companies
- Nuclear Receptor ROR Gamma - Therapeutics under Investigation
by Universities/Institutes
- Nuclear Receptor ROR Gamma - Pipeline Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Nuclear Receptor ROR Gamma - Products under Development by
Companies
- Nuclear Receptor ROR Gamma - Products under Investigation by
Universities/Institutes
- Nuclear Receptor ROR Gamma - Companies Involved in Therapeutics
Development
For more information about this report visit
http://www.researchandmarkets.com/research/7s4q9f/nuclear_receptor
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161026006288/en/
Research and MarketsLaura Wood, Senior
Managerpress@researchandmarkets.comFor E.S.T Office Hours Call
1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT
Office Hours Call +353-1-416-8900U.S. Fax: 646-607-1907Fax (outside
U.S.): +353-1-481-1716Related Topics: Immune Disorders Drugs